Some stocks are one-hit wonders, making a big splash when they first appear, then quickly fizzling into obscurity or oblivion. But for other stocks, that initial big move is only a preview for even bigger and better gains to come.

Today, we've listed three stocks that made some of the biggest upward moves over the past month, which we'll pair with the ratings issued by our Motley Fool CAPS community. The higher each stock's rating, the greater CAPS members' faith in that company's ability to keep on beating the market.


1 Month  % Change

CAPS Rating

Amarin (Nasdaq: AMRN)



Rubicon Minerals (NYSE: RBY)



iGo (Nasdaq: IGOI)



1-Month % change from Nov. 3 to Dec. 3; NR = not yet rated.

As the markets whipsaw to changes in second-half economic performance, the S&P 500 has been volatile. So before we get shaken out again, let's see why the CAPS community thinks some of these companies might continue to outperform the market.

A mighty temblor
We've known for a long time that fish oil wasn't snake oil for your health. The omega-3 fatty acids found in fish oil are known to reduce the risk of heart disease and stroke, while helping to reduce symptoms of hypertension and depression, among other debilitating ailments. They may even prove effective against Alzheimer's.

Biotech Amarin published new study results last week for its medicinal-grade fish-oil drug, AMR101. In the tests, AMR101 significantly lowered triglyceride levels without raising "bad" LDL cholesterol, while meeting all of its endpoints for safety. Key to the results is that the safety profile may be superior to even that of GlaxoSmithKline's Lovaza, currently the only approved omega-3 treatment for high triglycerides.

The success of the trials has spurred Amarin to move up the date for submission to the FDA from 2012 to sometime next year, which suddenly makes the biotech an interesting takeover candidate. Glaxo's Lovaza may soon face generic competition, as Teva Pharmaceuticals (Nasdaq: TEVA) and others have filed notice to market generic versions on patents expiring as early as 2013. The drug enjoyed strong sales growth in 2009 with revenue jumping 31% from the year before, and increasing its U.S. market share by 33%. Glaxo just might be interested in adding Amarin to its fold, since Lovaza helped the pharmaceutical offset a 13% decline in overall revenue in the U.S., and the better safety profile of AMR101 would offset the sting of a generic Lovaza.

Some 77% of the CAPS members who've rated Amarin believe it will outperform the broad market averages. They undoubtedly agree with SorrySam's assessment that it's an all-around better prospect: "Postive phase 3 trials that lower triglycerides while not raising ldl cholestoral. Its competitor raises ldl cholestoral."

Let us know on the Amarin CAPS page whether you think GlaxoSmithKline or someone else will go for Amarin hook, line, and sinker.

A sunny disposition
Rubicon Mineral's flagship Phoenix project in the middle of the prolific Red Lake district has the potential to become a major gold producer. Goldcorp (NYSE: GG) was willing to pay a premium for Gold Eagle Mines' Bruce Channel discovery adjacent to Rubicon's, and a steady diet of good news coming out of the Phoenix project has stoked the fires of anticipation.

Well, Rubicon was on the move again the other day, after reporting that results from a large drilling effort showed exceptionally high concentrations of gold within the ore body, grading at 20.1 grams per ton. It almost doesn't matter what the price of gold is; Phoenix will be a profitable venture regardless.

Several weeks ago, CAPS member segundo100 said the pending report from Rubicon created a smart buying opportunity:

By the end of November 2010, Rubicon Minerals is to disclose a report about the quantities of gold in a large drilling. It is believed that Rubicon owns a great gold resource so this official disclosure should make the share price go up (which has seen periods of lows because shareholders sell based on misinformation or fear). I believe the time to buy is now.

You can follow along with Rubicon's development by adding the stock to your watchlist and having all the Foolish news and analysis gathered together for you in one place.

A speedy opportunity
iGo hasn't sparked enough interest among CAPS members yet to generate a star rating, but the handful who have weighed in are unanimous in their opinion that the company will pump out market-beating results.

iGo makes accessories for mobile electronic devices, including laptop chargers and universal power adapters for many different devices such as Cisco's Flip Video camera. In the third quarter, iGo's relationship with RadioShack (NYSE: RSH) helped boost revenue sequentially. The company also signed a deal with Texas Instruments (NYSE: TXN) to jointly develop custom integrated circuits.

spiritgate says iGo is only in the first inning of a very long game:

iGoi is just revving up and about to put several products on the market in 2011. they have enough backing to become a major player in the accessories market. Their niche is that their products save energy and are ecologically sound. One way to go with this company. UP!

Be sure to add it into the Fool's free portfolio tracker, and head over to the iGo CAPS page and accessorize it with your own comments on its future.

Shake, rattle, and roll
With these stocks shaking the market this past month it pays to start your own research on them at Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made all from a stock's CAPS page.

GlaxoSmithKline is a Motley Fool Global Gains choice. The Fool has written calls (Bull Call Spread) on Cisco. The Fool owns shares of and has written covered calls on GlaxoSmithKline. The Fool also owns shares of Teva Pharmaceutical and Texas Instruments. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. You can shake, rattle, and roll The Motley Fool's disclosure policy, but it still won't break.